Amelubant
As of the edition of 20 October 2026, Amelubant is a small molecule: stopped in 2013; acts on LTB4R.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2013
- Kind
- Small molecule
- Registered trials
- 14, 1 stopped early
- Disease areas
- Lungs and airways; Digestive system; Immune system; Bones, joints and muscles; Inherited and neonatal; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Amelubant.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| LTB4R | Leukotriene B4 receptor 1 | Q15722 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 9 | 9 | 0 | 0 |
| Phase 2 | 5 | 4 | 0 | 1 |
| All trials | 14 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Boehringer Ingelheim | Lead sponsor of trials | 1998 to now |